SubHero Banner

Keytruda® (pembrolizumab) – New and updated indications

October 24, 2016 – The FDA announced the approval of Merck’s Keytruda (pembrolizumab) for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [(tumor proportion score (TPS) ≥ 50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Download PDF